ácido lignocérico

Lignoceric Acid (Tetracosanoic Acid): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Lignoceric acid, or tetracosanoic acid, is the saturated fatty acid with formula C₂₃H₄₇COOH. It owes its name to the fact that it was first found in beechwood tar, discovered in 1888 by Hell and Hermanns. It belongs to the group of saturated fatty acids, having no double bond, and is denoted in shorthand notation as 24:0. It is also a member of the group called very long-chain fatty acids (VLCFAs), a designation applied to fatty acids from 20 carbon atoms onwards.

The compound's several systematic and common names in use across scientific and commercial contexts include:

• IUPAC name: tetracosanoic acid
• Common name: lignoceric acid
• Synonyms: carnaubic acid, N-tetracosanoic acid, tetracosoic acid, C24:0 acid
• CAS Registry Number: 557-59-5; PubChem CID: 11197; Molecular formula: C₂₄H₄₈O₂; Molecular weight: 368.64 g/mol
• Abbreviated designations: C24:0, FA 24:0

Physical Properties

Lignoceric acid features a linear structure represented as CH₃(CH₂)₂₂COOH, and exhibits physical properties including a melting point of 80–82 °C, a boiling point of approximately 406 °C, and a density of about 0.9 g/cm³. In purified form it is a crystalline fatty acid with a melting point at 87.5–88 °C and a boiling point at 272 °C at 10 mmHg. ChEBI classifies it as a C24 straight-chain saturated fatty acid.

Lipid Map Classification

In the LIPID MAPS Structure Database (LMSD), lignoceric acid is categorized under Fatty Acyls [FA], Fatty Acids and Conjugates [FA01], Straight chain fatty acids [FA0101].

2. Natural Sources and Occurrence

Plant and Botanical Sources

Lignoceric acid is found in wood tar, various cerebrosides, and in small amounts in most natural fats. The fatty acids of peanut oil contain small amounts of lignoceric acid, ranging from 1.1% to 2.2%. It occurs as a glycerol ester as a minor constituent of many plant fats; it is found especially in wood tar, as from beechwood and rotten oak wood, as well as in peanut oil.

Generally, vegetable oils contain a low amount of lignoceric acid. For example, the lignoceric acid content in olive oil ranges from 0.5–1% and in peanut oil from 1–2.2%. Lignoceric acid is found naturally in vegetable oils such as rapeseed oil and canola oil, as well as in animal fats such as those of fish and mammals, in cottonseed oil, and in the seeds of the Japanese lignoceric nut.

Lignoceric acid (tetracosanoic acid, C24:0) is a saturated fatty acid occurring as a component of plant-derived lipids. It has been identified from Populus tremuloides (trembling aspen). It is found in wood extractives and tall oil fractions of coniferous trees, is usually present at trace amounts in microalgae and seaweeds, and edible mushrooms also contain a low quantity of lignoceric acid.

Industrial and Secondary Sources

This fatty acid is also a byproduct of lignin production. Lignoceric acid is primarily extracted from natural sources such as beechwood tar or through distillation of rotten oak wood, where it occurs as a minor component in lignocellulosic materials. Alternatively, it can be obtained as a byproduct from the processing of tall oil or plant waxes like sugarcane wax, which contain lignoceric alcohol as a precursor.

Biological and Endogenous Occurrence in Mammals

Lignoceric acid (tetracosanoic acid) is a saturated fatty acid with a 24-carbon backbone that occurs naturally in wood tar, various cerebrosides, and in small amounts in most natural fats. In mammals, it is found in cerebrosides and is synthesized during brain development. Lignoceric acid serves as a key component of cerebrosides, which are essential lipids in the myelin sheath of nerve tissues.

As a constituent of membrane phospholipids, lignoceric acid is involved in various cellular functions. In plants, lignoceric acid is involved in the formation of plant structures serving barrier protection. Specifically, it is involved in the biosynthesis of cuticular waxes. In addition, hydroxylignoceric acid acts as one of the building blocks of the suberin polymer.

3. Historical Discovery and Traditional Context

Lignoceric acid owes its name to the fact that it was found in beechwood tar, discovered in 1888 by Hell and Hermanns. Lignoceric acid, a saturated very long-chain fatty acid, is naturally present in various plant and animal fats, notably in peanut oil and certain cereals. Historically, its identification dates back to the 19th century, where it was characterized as a component of complex lipids in biological membranes.

Lignoceric acid does not have a well-documented traditional medicinal history as an isolated compound. It has never been used as a standalone therapeutic preparation in any historically recorded ethnomedicinal system. Its earliest recognition was purely chemical and analytical. However, it occurs naturally as a minor constituent in plant oils and foods used by many populations globally, and has been identified as a component of Terminalia sericea, a tree used in African traditional medicine. Aliphatic compounds isolated from such plants, including tetracosanoic acid (lignoceric acid), were identified in the context of anti-diabetes mellitus research (Watanabe et al., 1977). Nonetheless, direct attribution of therapeutic intent specifically to lignoceric acid in traditional medicine cannot be confirmed from available peer-reviewed sources, and any broader historical use of lignoceric acid was incidental to the use of the plant materials containing it.

Over time, lignoceric acid has attracted scientific interest for its structural and metabolic roles in human physiology. It can be easily reduced to lignoceryl alcohol, and the biological activities of lignoceric acid are considered least explored compared to shorter-chain fatty acids.

4. Key Constituents, Related Compounds, and Metabolic Context

Relationship to Other Very Long-Chain Fatty Acids

Very long-chain saturated fatty acids (VLCSFAs) — including arachidic acid (C20:0), behenic acid (C22:0), and lignoceric acid (C24:0) — have gained scientific interest due to their potentially different effects on health compared to shorter-chain saturated fats. In contrast to other saturated fatty acids, very long-chain saturated fatty acids (VLSFAs) have received limited attention. Reviews have aimed to summarize the associations of VLSFAs, including arachidic acid, behenic acid, and lignoceric acid, with cardiovascular disease outcomes and type 2 diabetes.

Role in Sphingolipid Biochemistry

The hydroxy fatty acids (hFA) found in sphingolipids include, but are not limited to, palmitic acid (C16:0), stearic acid (C18:0), docosanoic acid (C22:0; behenic acid), and tetracosanoic acid (C24:0; lignoceric acid). Research highlights that lignoceric acid is an important constituent of sphingolipids, which are vital for nerve cell membrane integrity and function.

Lignoceric acid serves as a key component of cerebrosides and can undergo alpha-hydroxylation to form cerebronic acid, contributing to the structural integrity and function of myelin lipids. This hydroxylation reaction, converting lignoceric acid to cerebronic acid (2-hydroxylignoceric acid), was studied extensively in developing brain tissue. Alpha-hydroxylation of lignoceric acid (n-tetracosanoic acid) to cerebronic acid (2-hydroxylignoceric acid) by postnuclear preparations of brains from developing rat, mouse, and several neurological mouse mutants was studied.

Ceramide Formation and Skin Biology

Ceramides belong to sphingolipids, an important group of cellular and extracellular lipids. Their physiological functions range from cell signaling to participation in the formation of barriers against water evaporation. In the skin, they are essential for the permeability barrier, together with free fatty acids and cholesterol. Lipid films composed of ceramides — specifically N-lignoceroyl 6-hydroxysphingosine (CerNH24) and N-lignoceroyl sphingosine (CerNS24) — along with lignoceric acid (LIG; 24:0) and cholesterol have been studied for their periodic structure and permeability properties.

Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin. Contrary to previous assumptions that ceramides and other sphingolipids found in cell membranes were purely supporting structural elements, ceramide can participate in a variety of cellular signaling, including regulating differentiation, proliferation, and programmed cell death.

5. Mechanisms of Action

Peroxisomal Beta-Oxidation

The primary established biochemical pathway for lignoceric acid catabolism in mammals is peroxisomal beta-oxidation. The deficient oxidation and accumulation of very-long-chain fatty acids in the Zellweger cerebro-hepato-renal syndrome (CHRS) and X chromosome-linked adrenoleukodystrophy (ALD), coupled with the observation that peroxisomes are lacking in CHRS, prompted investigation of the subcellular localization of the catabolism of lignoceric acid (C24:0).

In peroxisomes, lignoceric acid was oxidized at 7 times higher rate than in mitochondria. Mitochondria were able to oxidize lignoceric acid efficiently only when supplemented with lignoceroyl-CoA ligase activity from microsomes or myelin. The oxidation of lignoceric acid had an absolute requirement for CoASH and ATP; it was stimulated by NAD and FAD by 400% and 280%, respectively, whereas addition of carnitine and KCN had no effect. These properties confirm that in brain, lignoceric acid is oxidized in peroxisomes.

These results show that in brain, lignoceric acid is oxidized in peroxisomes and that lignoceroyl-CoA ligase activity is localized in peroxisomes and microsomes, but not in mitochondria. In liver and skin fibroblasts, mitochondria lack lignoceroyl-CoA ligase, so fatty acids are exclusively oxidized in peroxisomes in those tissues.

Alpha-Hydroxylation to Cerebronic Acid

Sphingolipid alpha-hydroxylase (Scs7p) is a membrane-bound protein belonging to the hydroxylase/desaturase family of enzymes that utilize a dimetal center to hydroxylate or desaturate lipid-based substrates. Scs7p specifically hydroxylates the alpha-carbon of the very-long-chain fatty acid moiety of sphingolipid precursor molecules that are prevalent in the myelin sheath and epidermis, where they play a stabilizing role.

Alpha-hydroxylation of lignoceric acid to cerebronic acid (2-hydroxylignoceric acid) by postnuclear preparations of brains from developing rat, mouse, and several neurological mouse mutants was studied. Preparations of brains from jimpy and myelin synthesis deficiency (msd) mice were found to synthesize cerebronic acid at less than 10% of their control rates, and those from quaking and dilute-lethal mice at approximately 30% and 50%, respectively. The apparent low rate of in vitro hydroxylation by brains of the mutant mice appeared to be due to decreased synthesis rather than increased oxidation of cerebronic acid.

Role in Myelination

The developmental pattern of the synthesis of both non-hydroxy and hydroxyceramide from free lignoceric acid in a brain-specific pathway requiring NADPH and cytosolic factors was similar to the synthesis from lignoceroyl-CoA, and both showed increasing activity during myelination. Lignoceric acid is thus not simply a dietary or structural molecule but a biosynthetically active substrate during a critical developmental window.

Membrane Structural Role

Ceramide-based lipids self-aggregate in cell membranes and form separate phases less fluid than the bulk phospholipids. These sphingolipid-based microdomains, or "lipid rafts," were originally proposed to sort membrane proteins along the cellular pathways of membrane transport. At present, most research focuses on their organizing function during signal transduction. Lignoceric acid, incorporated into ceramide moieties, contributes to the biophysical properties of these membrane domains.

6. Scientific Evidence by Area of Use

6.1 Neurological Disorders: X-Linked Adrenoleukodystrophy (X-ALD) and Zellweger Syndrome

The most extensively studied role of lignoceric acid in disease contexts is as a biochemical marker and metabolic participant in peroxisomal disorders, particularly X-linked adrenoleukodystrophy (X-ALD) and Zellweger cerebro-hepato-renal syndrome (CHRS).

The deficient peroxisomal oxidation of very-long-chain fatty acids, including lignoceric acid, contributes to certain syndromes, including Zellweger cerebro-hepato-renal syndrome and X chromosome-linked adrenoleukodystrophy.

In a foundational 1984 study published in Proceedings of the National Academy of Sciences (Singh et al.), peroxisomal and mitochondrial fractions were isolated from rat liver to determine the subcellular site of lignoceric acid catabolism. In Zellweger's syndrome, and to a lesser extent in infantile Refsum's disease, there was an increase in 24:0, 26:0, 26:1, and a number of even longer chain fatty acids. Zellweger fibroblasts in culture took up lignoceric, phytanic, and stearic acids and incorporated them into a variety of lipids in a manner comparable to control fibroblasts. However, these cells were unable to convert phytanic or lignoceric acid to CO₂.

Homogenates of fibroblasts from all patients with biochemical evidence of accumulation of very long-chain fatty acids showed normal or near-normal stearic acid beta-oxidation, but were deficient in lignoceric acid beta-oxidation. Residual lignoceric acid beta-oxidation activity varied from approximately 15% in Zellweger syndrome up to 50% in X-linked adrenoleukodystrophy. It is postulated that the accumulation of very long-chain fatty acids results from defects in peroxisomal beta-oxidation.

A 1988 study (Lazo et al., PNAS) demonstrated peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. This finding established a specific enzymatic defect connecting lignoceric acid metabolism to clinical neurological disease. The evidence in this area is strong at the biochemical level (cell-based and animal studies), well replicated, and forms the basis for using plasma VLCFA levels — including C24:0 — as diagnostic biomarkers for X-ALD.

Evidence strength: Robust biochemical and cell-based evidence; animal model data; clinical diagnostic utility confirmed. No controlled human intervention trials exist for supplemental lignoceric acid in these conditions.

6.2 Cardiovascular Disease and Cardiometabolic Health

A substantial body of observational epidemiological research has examined circulating levels of lignoceric acid (C24:0) and cardiovascular outcomes. This line of research treats circulating lignoceric acid as an integrated biomarker of diet and endogenous metabolism rather than studying supplemental administration.

Saturated fatty acids with different chain lengths have different biological activities, but little is known about very long-chain saturated fatty acids (VLCSFAs). One community-based cohort study included 2,198 adults without carotid artery plaques (CAPs) at baseline. The percentage of baseline erythrocyte VLCSFA — arachidic acid (C20:0), behenic acid (C22:0), and lignoceric acid (C24:0) — was measured by gas chromatography, and the presence of CAPs was determined at baseline and every 3 years thereafter by ultrasound examination. A meta-analysis was conducted to summarize the pooled associations between circulating VLCSFAs and the risk of cardiovascular diseases.

Multivariate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of carotid artery plaques for the highest versus lowest quartile were 0.75 (0.59–0.94) for C24:0 in women. The pooled HRs (95% CIs) of CVDs for the highest versus lowest circulating VLCSFAs from seven studies including 8,592 participants and 3,172 CVD events were 0.57 (0.42–0.79) for C24:0.

A 2022 review article in Current Atherosclerosis Reports summarized these findings: the purpose of this review was to summarize the associations of VLSFAs, including arachidic acid, behenic acid, and lignoceric acid, with cardiovascular disease outcomes and type 2 diabetes. In an early report from the EPIC-Interact study, the investigators observed that VLSFAs were associated with lower risk of incident diabetes, whereas saturated fatty acids with 18 carbons or less were associated with higher risk. VLSFAs have been associated with reduced risk of several cardiovascular outcomes.

Very long-chain saturated fatty acids (VLCSFA) may influence cardiometabolic health differently from other, often detrimental, saturated fatty acids. Evidence remains inconclusive, partly because VLCSFA are metabolically derived from SFA, making it difficult to disentangle their individual effects due to potential confounding of correlated lipids. Prior studies rarely accounted for correlations with other lipids or did not consider VLCSFA-specific lipid classes. A nested case-cohort analysis investigated prospective associations of circulating VLCSFA (C20:0, C22:0, C24:0) across multiple plasma lipid classes with type 2 diabetes (T2D) and cardiovascular disease (CVD), accounting for confounding by correlated lipids. This was conducted within the EPIC-Potsdam cohort: 1,911 in the T2D case-cohort (774 cases); 1,704 in the CVD case-cohort (547 cases).

This study highlights that VLCSFA associations with disease depend on the specific lipid classes carrying them, cautioning against treating saturated fats as a single uniform group and suggesting that class-specific VLCSFA measures could enhance risk assessment and prevention strategies for type 2 diabetes and cardiovascular disease.

A systematic review and meta-analysis of circulating VLCSFA studies noted: Recent observational studies have documented inverse associations of circulating very long-chain saturated fatty acids (VLCSFAs), namely arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0), with cardiometabolic outcomes. In addition to their endogenous production, it has been suggested that dietary intake or an overall healthier lifestyle may influence VLCSFA concentrations.

Evidence strength: Multiple large prospective cohort studies and meta-analyses show consistent inverse associations between circulating C24:0 and cardiovascular events. However, all evidence is observational; circulating VLCSFAs are integrated biomarkers of both diet and endogenous elongation, and causality has not been established. No interventional (RCT) data for lignoceric acid supplementation in cardiovascular endpoints exist in the peer-reviewed literature.

6.3 Healthy Aging

A prospective cohort study utilizing 1992–2014 data from the Cardiovascular Health Study (CHS), a multicenter, population-based study of cardiovascular disease among older adults, was conducted. Among 4,559 CHS participants with available fatty acid data, 1,879 were excluded due to a prior age-related event before their first measurement; the remaining 2,680 participants were included in the analyses. Plasma phospholipid VLSFA levels were measured by thin-layer chromatography followed by gas chromatography. The main outcome was the hazard ratio of an incident unhealthy aging event associated with serial measures of plasma arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0). Among the 2,680 study participants, the mean age was 74.7 years at entry and 36.4% were male. During a median 7.5 years of follow-up, 2,484 participants experienced an unhealthy event.

The strongest association was with 24:0 (lignoceric acid). When compared with the lowest quintile, the quintile with the highest levels of 24:0 was associated with a 16% lower risk of an unhealthy aging event (95% CI, 5%–27%), after adjustment for demographics, lifestyle factors, and diabetes.

These findings suggest that higher levels of circulating behenic acid and lignoceric acid are associated with lower risk of unhealthy aging events. These results highlight the need to explore determinants of circulating VLSFAs for potential novel efforts to promote healthy aging.

Evidence strength: Single large prospective cohort study with serial biomarker measurements; results are associative. The unhealthy aging composite endpoint encompasses incident chronic diseases, physical dysfunction, and cognitive decline. Causality is not established.

6.4 Heart Failure

Circulating very-long-chain saturated fatty acids (VLSFAs) are integrated biomarkers of diet and metabolism that may point to new risk pathways and potential targets for heart failure prevention. The associations of VLSFA to heart failure in humans have been studied in a cohort study design examining associations of serially measured plasma phospholipid VLSFA with incident heart failure in the Cardiovascular Health Study. The study investigated associations of time-varying levels of the three major circulating VLSFAs — lignoceric acid (24:0), behenic acid (22:0), and arachidic acid (20:0) — with the risk of incident heart failure using Cox regression.

Evidence strength: Observational cohort data only; no intervention data. Preliminary and requires replication with attention to confounding.

6.5 Type 2 Diabetes

Very-long-chain saturated fatty acids (VLCSFAs), such as arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0), have demonstrated inverse associations with cardiometabolic conditions, although more evidence is needed to characterize their relation with risk of type 2 diabetes (T2D). Little is known regarding their potential dietary and lifestyle predictors. One study aimed to examine the association of plasma and erythrocyte concentrations of VLCSFAs with incident T2D risk, using existing measurements of fatty acid concentrations in plasma and erythrocytes among 2,854 and 2,831 participants in the Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS), respectively.

Very long-chain saturated fatty acids may influence cardiometabolic health differently from other, often detrimental, saturated fatty acids. Evidence remains inconclusive, partly because VLCSFA are metabolically derived from SFA, making it difficult to disentangle their individual effects due to potential confounding of correlated lipids.

Evidence strength: Prospective observational evidence from large cohorts (EPIC-InterAct, NHS/HPFS) is generally inverse and directionally consistent, but causality is unproven. No randomized trial data are available.

6.6 Skin Barrier Function

Lignoceric acid's role in skin biology is studied primarily through its presence in ceramide molecules used in models of stratum corneum structure. Ceramides belong to a family of sphingolipids, are important regulators of cellular processes, and are essential components of the skin permeability barrier. This barrier resides in the uppermost epidermal layer, the stratum corneum (SC), which consists of corneocytes surrounded by a lamellar lipid matrix. To prevent excess water loss and the entry of undesired compounds from the environment, organization of the SC lipids is highly specialized.

Studies investigated simple lipid membrane models composed of N-lignoceroyl-sphingosine (Cer NS), lignoceric acid (LA), cholesterol, and cholesteryl sulfate to examine effects of ceramide concentration on lamellar phase formation and permeability.

Evidence strength: Biophysical and cell-membrane model studies only (in vitro). No human clinical trials for topical or oral lignoceric acid specifically targeting skin barrier function.

7. Body Systems and Health Areas of Scientific Association

• Nervous system / myelin biology: Lignoceric acid is synthesized during brain development and is found in cerebrosides. Deficient peroxisomal oxidation of very-long-chain fatty acids, including lignoceric acid, contributes to Zellweger cerebro-hepato-renal syndrome and X chromosome-linked adrenoleukodystrophy.
• Peroxisomal metabolism: Lignoceric acid is preferentially catabolized in peroxisomes via beta-oxidation, and its accumulation is a diagnostic feature of peroxisomal biogenesis disorders.
• Cardiovascular system: Higher circulating C24:0 levels are inversely associated with cardiovascular events in multiple epidemiological datasets.
• Metabolic health / type 2 diabetes: Observed inverse associations between C24:0 and incident diabetes in large European and American cohorts.
• Skin and epithelial barrier: The physiological functions of ceramides (of which lignoceric acid is a constituent acyl chain) range from cell signaling to participation in the formation of barriers against water evaporation; in the skin, they are essential for the permeability barrier, together with free fatty acids and cholesterol.
• Aging: Higher plasma phospholipid C24:0 is associated with lower risk of unhealthy aging events in prospective cohort data.

8. Dosage Forms and Reported Dosages

Lignoceric acid is not currently established as a mainstream dietary supplement with standardized dosage regimens backed by clinical trial data. While it is not a mainstream dietary supplement, interest in lignoceric acid has grown because of its roles in skin barrier structure (as part of ceramides), nerve cell membranes (sphingolipids), and its measurement as a biomarker in certain rare metabolic disorders.

Lignoceric acid does appear as a listed ingredient in the NIH Dietary Supplement Label Database (DSLD), indicating its presence in some marketed supplement formulations.

Dietary intake of lignoceric acid occurs incidentally through consumption of peanuts, peanut oil, canola oil, and other vegetable fats. The fatty acids of peanut oil contain small amounts of lignoceric acid, between 1.1% and 2.2%. In human epidemiological research, the exposure variable used has consistently been circulating plasma phospholipid or erythrocyte levels (measured as a proportion of total fatty acids by gas chromatography), not administered oral doses. No specific clinical dose of supplemental lignoceric acid has been established in human trials published in the peer-reviewed literature.

In laboratory research contexts, lignoceric acid is supplied as a purified compound (≥98–99% purity) for cell culture and biochemical assay purposes, and dissolved using agents such as alpha-cyclodextrin. Alpha-cyclodextrin at concentrations of 1–8 mM helps dissolve, in aqueous solution, fatty acids such as lignoceric, stearic, and palmitic acids and complex lipids such as ceramide and cerebroside. Formation of an inclusion complex was indicated on examination of the solution by gel filtration. Alpha-cyclodextrin strikingly increased synthesis of ceramide from sphingosine and either free lignoceric or stearic acid by rat brain preparations.

9. Safety Considerations

Lignoceric acid as an isolated supplemental compound has not undergone formal safety evaluation (toxicological profiling, no-observed-adverse-effect level [NOAEL] determination, or human safety trials) that is documented in accessible peer-reviewed or regulatory databases. The following considerations are grounded in biochemical and epidemiological data:

Endogenous Presence and Dietary Exposure

Lignoceric acid is an endogenous constituent of human tissues and is consumed in trace amounts in a normal diet through peanuts, vegetable oils, and other common foods. From a nutritional perspective, lignoceric acid's direct health benefits in humans have not been extensively validated through clinical trials. Current evidence primarily focuses on its biochemical presence and metabolism rather than specific physiological effects.

Peroxisomal Disease Context

In individuals with intact peroxisomal function, dietary lignoceric acid is metabolized normally in peroxisomes. In patients with peroxisomal biogenesis disorders such as Zellweger syndrome or X-ALD, homogenates of fibroblasts from all patients with biochemical evidence of accumulation of very long-chain fatty acids showed normal or near-normal stearic acid beta-oxidation, but were deficient in lignoceric acid beta-oxidation. Residual lignoceric acid beta-oxidation activity varied from approximately 15% in Zellweger syndrome up to 50% in X-linked adrenoleukodystrophy. This implies that supplemental delivery of lignoceric acid to such patients could potentially worsen VLCFA accumulation; however, this specific concern has not been evaluated in human intervention studies.

Epidemiological Safety Signal

Observational data from large cohorts have not identified adverse outcomes associated with higher circulating levels of lignoceric acid. Findings from multiple studies suggest that circulating VLCSFAs were inversely associated with cardiovascular health events, meaning higher levels were associated with better, not worse, outcomes. However, these associations relate to endogenous circulating levels, not supplemental ingestion.

Distinction from Shorter-Chain Saturated Fatty Acids

Saturated fatty acids have traditionally been associated with increased risk of cardiovascular disease, leading to recommendations to limit their intake. However, emerging evidence shows that not all saturated fatty acids affect cardiometabolic health equally, as their effects may vary depending on chemical structure. Very long-chain saturated fatty acids like lignoceric acid are metabolically and biochemically distinct from the shorter-chain saturated fatty acids (e.g., palmitic acid) most implicated in adverse cardiometabolic effects.

Absence of Known Drug Interactions

No documented pharmacokinetic drug interactions for lignoceric acid are described in the peer-reviewed literature or major regulatory databases. As a naturally occurring dietary fatty acid, it is not expected to interfere with cytochrome P450 enzyme systems based on available biochemical data; however, formal interaction studies have not been conducted.

10. Current Research Status and Limitations

Lignoceric acid's inclusion in nutritional formulations is supported by its natural occurrence in commonly consumed foods and its role in maintaining cellular structures. While more rigorous clinical research is needed to clarify the distinct health effects of lignoceric acid supplementation, existing knowledge affirms its importance as a naturally occurring dietary fatty acid.

Very long-chain saturated fatty acids may influence cardiometabolic health differently from other, often detrimental, saturated fatty acids. Evidence remains inconclusive, partly because VLCSFAs are metabolically derived from SFA, making it difficult to disentangle their individual effects due to potential confounding of correlated lipids.

A critical methodological challenge in all epidemiological research on lignoceric acid is that circulating levels reflect a composite of dietary intake (from peanuts, vegetable oils, etc.) and endogenous fatty acid chain elongation (via elongase enzymes, notably ELOVL1). Dietary exposure cannot be cleanly separated from metabolic production. Furthermore, in addition to their endogenous production, it has been suggested that dietary intake or an overall healthier lifestyle may influence VLCSFA concentrations; however, a systematic review of the modifiable lifestyle contributors to circulating VLCSFAs is lacking.

In sum, lignoceric acid occupies a scientifically interesting position: it is a well-characterized endogenous molecule with clearly defined roles in neural myelination and membrane structure, with epidemiological signals suggesting favorable cardiometabolic associations. However, as of the available evidence, no randomized controlled trial has evaluated the effect of supplemental lignoceric acid on any clinical health outcome in humans.

References

• LIPID MAPS Structure Database — Lignoceric Acid (LMFA01010024)
• Wikipedia — Lignoceric acid
• Tuscany Diet — Lignoceric acid
• Celignis Biomass Analysis Laboratory — Lignoceric Acid
• NCATS Inxight Drugs — Lignoceric Acid
• ScienceDirect Topics — Lignoceric Acid (Biochemistry overview)
• ScienceDirect Topics — Lignoceric Acid (Pharmacology overview)
• Singh I et al. (1984). Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci USA 81(13):4203–4207. PubMed PMID: 6588384
• Singh I et al. (1984). Lignoceric acid is oxidized in the peroxisome (PMC full text). PMC345397
• Lazo O et al. (1993). Purification of peroxisomes and subcellular distribution of enzyme activities for activation and oxidation of very-long-chain fatty acids in rat brain. PubMed PMID: 8399326
• Singh I (1989). Mitochondrial and Peroxisomal β-Oxidation of Stearic and Lignoceric Acids by Rat Brain. Journal of Neurochemistry
• Peroxisomal oxidation of lignoceric acid in rat brain. Neurochemical Research, Springer
• Murad S and Kishimoto Y (1975). Alpha hydroxylation of lignoceric acid to cerebronic acid during brain development. PubMed PMID: 1150661
• Poulos A et al. (1986). Accumulation and defective beta-oxidation of very long chain fatty acids in Zellweger's syndrome, adrenoleukodystrophy and Refsum's disease variants. Clin Genet. PubMed PMID: 2427264
• Bockus LB et al. (2021). Assessment of Plasma Phospholipid Very-Long-Chain Saturated Fatty Acid Levels and Healthy Aging. JAMA Network Open. PubMed PMID: 34383061
• Bockus LB et al. (2021). Assessment of Plasma Phospholipid Very-long-chain Saturated Fatty Acid Levels and Healthy Aging: The Cardiovascular Health Study. PMC8571866
• Circulating Very-Long-Chain Saturated Fatty Acids Were Inversely Associated with Cardiovascular Health: A Prospective Cohort Study and Meta-Analysis. PubMed PMID: 32899794
• Very long-chain saturated fatty acids and diabetes and cardiovascular disease (2022 review). PMC8702474
• Lifestyle Factors Associated with Circulating Very Long-Chain Saturated Fatty Acids in Humans: A Systematic Review. PMC10102996
• Forouhi NG et al. (2014). Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. PMC4196248
• Very long-chain saturated fatty acids in plasma lipids: association with cardiometabolic risk influenced by lipid interactions. Cardiovascular Diabetology, Springer (2025)
• Polymorphism, Nanostructures, and Barrier Properties of Ceramide-Based Lipid Films. ACS Omega
• Omega-O-Acylceramides in Skin Lipid Membranes. Langmuir
• The Medical Biochemistry Page — Sphingolipid Metabolism and the Ceramides
• NIH Office of Dietary Supplements — Dietary Supplement Label Database: Lignoceric Acid
• Saturated fatty acid biomarkers and risk of cardiometabolic diseases: A meta-analysis of prospective studies. Frontiers in Nutrition (2022)